...
首页> 外文期刊>Clinical Chemistry >Maternal Plasma DNA Analysis with Massively Parallel Sequencing by Ligation for Noninvasive Prenatal Diagnosis of Trisomy 21
【24h】

Maternal Plasma DNA Analysis with Massively Parallel Sequencing by Ligation for Noninvasive Prenatal Diagnosis of Trisomy 21

机译:母体血浆DNA分析与结扎大规模平行测序的21三体性无创产前诊断。

获取原文
获取原文并翻译 | 示例
           

摘要

Noninvasive prenatal diagnosis of trisomy 21 (T21) has recently been shown to be achievable by massively parallel sequencing of maternal plasma on a sequencing-by-synthesis platform. The quantification of several other human chromosomes, including chromosomes 18 and 13, has been shown to be less precise, however, with quantitative biases related to the chromosomal GC content. Maternal plasma DNA from 10 euploid and 5 T21 pregnancies was sequenced with a sequencing-by- ligation approach. We calculated the genomic representations (GRs) of sequenced reads from each chromosome and their associated measurement CVs and compared the GRs of chromosome 21 (chr21) for the euploid and T21 pregnancies. We obtained a median of 12 × 10^sup 6^ unique reads (21% of the total reads) per sample. The GRs deviated from those expected for some chromosomes but in a manner different from that previously reported for the sequencing-by-synthesis approach. Measurements of the GRs for chromosomes 18 and 13 were less precise than for chr21. z Scores of the GR of chr21 were increased in the T21 pregnancies, compared with the euploid pregnancies. Massively parallel sequencing-by-ligation of maternal plasma DNA was effective in identifying T21 fetuses noninvasively. The quantitative biases observed among the GRs of certain chromosomes were more likely based on analytical factors than biological factors. Further research is needed to enhance the precision for measuring for the representations of chromosomes 18 and 13.
机译:最近已证明,通过在合成测序平台上对母体血浆进行大规模平行测序,可以实现21三体性疾病(T21)的无创产前诊断。已显示对其他几条人类染色体(包括18号和13号染色体)的定量精确度较低,但是存在与染色体GC含量有关的定量偏差。用连接测序法对来自10个整倍体和5个T21妊娠的孕妇血浆DNA进行测序。我们计算了每个染色体及其相关测量CV的测序读物的基因组表示(GRs),并比较了整倍体和T21怀孕的21号染色体(chr21)的GRs。每个样本我们获得了12×10 ^ sup 6 ^独特读数的中位数(占总读数的21%)。 GR偏离了某些染色体的预期遗传值,但方式与先前报道的合成测序方法不同。 18和13号染色体GRs的测量精度不如chr21。 z与整倍体妊娠相比,chl21的GR得分在T21妊娠中增加。通过母体血浆DNA的连接进行大规模平行测序可有效地无创地鉴定T21胎儿。基于分析因素而不是生物学因素,在某些染色体的遗传资源之间观察到的定量偏倚更有可能。需要进行进一步的研究以提高测量18号和13号染色体表示的精度。

著录项

  • 来源
    《Clinical Chemistry》 |2010年第3期|p.459-463|共5页
  • 作者单位

    Rossa W.K. Chiu,1,2 Hao Sun,1,2 Ranjit Akolekar,3 Christopher Clouser,4 Clarence Lee,4 Kevin McKernan, 4 Daixing Zhou,4 Kypros H. Nicolaides,3 and Y.M. Dennis Lo1,2*1 Centre for Research into Circulating Fetal Nucleic Acids, Li Ka Shing Institute of Health Sciences, and 2 Department of Chemical Pathology, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong SAR, China, 3 Harris Birthright Research Centre for Fetal Medicine, King's College Hospital, London, UK, 4 Life Technologies, Beverly, MA, * address correspondence to this author at: Department of Chemical Pathology, The Chinese University of Hong Kong, Rm. 38061, 1/F, Clinical Sciences Bldg., Prince of Wales Hospital, 30-32 Ngan Shing St., Shatin, Hong Kong SAR, China. Fax 852-2636-5090, e-mail loym@cuhk.edu.hk.Author Contributions: All authors confirmed they have contributed to the intellectual content of this paper and have met the following 3 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data, (b) drafting or revising the article for intellectual content, and (c) final approval of the published article.Authors' Disclosures of Potential Conflicts of Interest: Upon manuscript submission, all authors completed the Disclosures of Potential Conflict of Interest form. Potential conflicts of interest:Employment or Leadership: None declared.Consultant or Advisory Role: Y.M.D. Lo, Sequenom.Stock Ownership: C. Lee, Life Technologies, K. McKernan, Life Technologies, D. Zhou, Life Technologies, Y.M.D. Lo, Sequenom. Honoraria: None declared.Research Funding: R.W.K. Chiu and Y.M.D. Lo, Life Technologies, sponsor of the sequencing runs as part of a grant from the Innovation and Technology Fund (ITS/054/09), Y.M.D. Lo, Sequenom.Expert Testimony: None declared.Other Remuneration: R.W.K. Chiu and Y.M.D. Lo hold patents and have filed patent applications on the detection of fetal nucleic acids in maternal plasma for noninvasive prenatal diagnosis. Y.M.D. Lo was supported by an endowed professorship from the Li Ka Shing Foundation.Role of Sponsor: The funding organizations played no role in the design of study, choice of enrolled patients, review and interpretation of data, or preparation or approval of manuscript.Acknowledgments: We thank Elizabeth Levandowsky and Tristen Weaver for preparing the libraries and performing the sequencing.,;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号